Navigation Links
GenVec to Present at the 2011 10th Annual BIO Investor Forum
Date:10/18/2011

GAITHERSBURG, Md., Oct. 18, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting recent developments at the 2011 10th Annual BIO Investor Forum on Tuesday, October 25, 2011 at 3:00 p.m. PDT at the Palace Hotel in San Francisco.

A webcast of Dr. Fischer's presentation will be available both live and on replay. The presentation will be available via webcast at http://www.veracast.com/webcasts/bio/investorforum2011/14112492.cfm. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation may also be accessed via the investors and media section of the Company's Web site at http://ir.genvec.com under "Events & Presentations."

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission. Retail Investor and Media Contact:Institutional Investor Contact:GenVec, Inc.

S.A. Noonan CommunicationsDouglas J. Swirsky

Susan A. Noonan(240) 632-5510(212) 966-3650dswirsky@genvec.com

susan@sanoonan.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Renews Stockholder Rights Plan
2. GenVec Reports First Quarter 2011 Financial Results
3. GenVec Regains Compliance with NASDAQ Listing Requirements
4. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
5. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
6. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
7. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
8. GenVec Reports Third Quarter 2009 Financial Results
9. GenVec Announces Third Quarter 2009 Results Conference Call
10. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
11. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... On Thursday, March 23, 2017, ... down 0.07%; the Dow Jones Industrial Average edged 0.02% ... closed at 2,345.96, marginally dropping 0.11%. US markets saw ... 4 sectors finished in red, and 1 sector ended ... reports coverage on the following Biotechnology equities: BioDelivery Sciences ...
(Date:3/24/2017)... 2017 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ... cancer vaccines, today announced participation at the following conferences: ... Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" ... New York, NY . Agenus will participate ... 9:40 am: Robert B. Stein , M.D., Ph.D., ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 PMD Healthcare announces the ... and Wellness Management System (WMS), a remote, real-time lung ... 2010, PMD Healthcare is a Medical Device, Digital Health, ... dedicated to creating innovative solutions that empower people to ... intent focus, PMD developed the first ever personal spirometer, ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/2/2017)... LONDON , March 2, 2017 Who ... infringement lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... ON THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
Breaking Biology News(10 mins):